

**Docket No.: TJU0001-107  
PATENT**

**Serial No.: 10/621,684  
Filed: July 17, 2003**

**In the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

**1-22. (Canceled)**

- 23. (Currently Amended)** A pharmaceutical composition comprising:
- a) a ST receptor binding peptide; ligand;
  - b) a non-peptide radiostable active agent; and,
  - c) a pharmaceutical carrier or diluent.

**24. (Canceled)**

**25. (Previously presented)** The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides.

**26. (Previously presented)** The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.

**Docket No.: TJU0001-107  
PATENT**

**Serial No.: 10/621,684  
Filed: July 17, 2003**

**27. (Previously presented )** The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

**28. (Previously presented )** The pharmaceutical composition of claim 23 wherein said an active agent is a therapeutic agent.

**29. (Canceled)**

**30. (Previously presented )** The pharmaceutical composition of claim 23 wherein said an active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, and 1,4-benzoquinone derivatives.

**31. (Previously presented )** The pharmaceutical composition of claim 23 wherein said an active agent is 5-fluorouracil.

**32. (Previously presented)** The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides, and the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, and 1,4-benzoquinone derivatives.

**Docket No.: TJU0001-107  
PATENT**

**Serial No.: 10/621,684  
Filed: July 17, 2003**

**33. (Previously presented )** The pharmaceutical composition of claim 32 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.

**34. (Previously presented )** The pharmaceutical composition of claim 32 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

**35. (Canceled)**

**36. (Previously presented )** The pharmaceutical composition of claim 32 wherein said an active agent is 5-fluorouracil.

**37. (Canceled)**

**38. (Previously presented)** The pharmaceutical composition of claim 33 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

**39. (Previously presented)** The pharmaceutical composition of claim 33 wherein said an active agent is 5-fluorouracil.

**40. (Previously presented )** The pharmaceutical composition of claim 39 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

**41. (Previously presented )** The pharmaceutical composition of claim 23 wherein said pharmaceutical composition is an injectable pharmaceutical composition.

Docket No.: TJU0001-107  
PATENT

Serial No.: 10/621,684  
Filed: July 17, 2003

**42. (Currently Amended )** A pharmaceutical composition comprising:

- a) a ST receptor binding peptide; ~~ligand~~;
- b) a radiostable active agent; and,
- c) a pharmaceutical carrier or diluent;

wherein said pharmaceutical composition is a liposome comprising a vesicle matrix wherein the ST receptor binding ligand is in the vesicle matrix and the active agent is inside the liposome.

**43. (Previously presented )** The pharmaceutical composition of claim 42 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides, and the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.

**44. (Previously presented )** The pharmaceutical composition of claim 42 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2 said the active agent is 5-fluorouracil.

**Docket No.: TJU0001-107  
PATENT**

**Serial No.: 10/621,684  
Filed: July 17, 2003**

**45. (Previously presented)** The pharmaceutical composition of claim 42 wherein said ST receptor binding ligand is selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides.

**46. (Previously presented)** The pharmaceutical composition of claim 42 wherein the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.

**47. (Previously presented)** The pharmaceutical composition of claim 42 wherein the active agent is a non-peptide.